The approval of Aricept fifteen years ago was the last time there was anything new to treat the symptoms of Alzheimer’s disease. This lack of research and drug development is unnerving to patients and practitioners alike, with this lethal disease affecting 5.4 million Americans. On June 13, 2013 the BCC posted an alarming research report,[…]
Treatments Available for Surge of Alzheimer’s Cases
Anti-Alzheimer's, Antidimentia, Drug Research & Development API Tags: 120014-06-441100-52-1acetylcholineAlzheimers diseaseDonepezilMemantine Jul 02, 2013
Alzheimer’s Disease Is The Fastest Growing Health Threat To Americans
Anti-Alzheimer's, Antidimentia Tags: 120014-06-441100-52-1acetylcholineAlzheimers diseaseDonepezilMemantine Mar 12, 2013
A report issued from the University of Washington in Seattle on March 5, 2013 revealed a startling statistic. The fastest growing health threat to Americans is not cancer or heart disease – it is Alzheimers disease! While this may not have been surprising information to groups like the Alzheimer’s Association, who have been predicting an[…]
Cases of Dementia and Alzheimer’s Disease Rising, Memantine is a Viable Treatment
Anti-Alzheimer's, Antiparkinson Agent, Drug Research & Development API Tags: 41100-52-1Alzheimers diseaseDonepezilMemantine Jun 13, 2012
Memantine Hydrochloride, CAS number 41100-52-1, is an effective oral medication for treating patients with Alzheimer’s disease. Memantine is the first in a new and formidable class of Alzheimer’s drugs which work by blocking NMDA glutamate receptors. Known as it’s brand name Namenda, marketed in the United States by Forest Laboratories, memantine is typically prescribed for[…]
